Hot flashes in Menopause.
Conditions
Interventions
Intervention 1: The experimental group will be taken one capsule 400 IU vitamin E (soft gelatin capsule) daily during two phases that each of them lasts 28 days. Intervention 2: The control group will
Sponsors
Vice chancellor for research, Guilan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
45 Years to 60 Years
Inclusion criteria
Inclusion criteria: Having an age range of 45-60 years old for healthy menopausal women Passing at least 12 consecutive months from the end of the last menstrual period Having at least one hot flash per day based on the item of flushing/sweating in Modified Kupperman Index
Exclusion criteria
Exclusion criteria: Having Vaginal bleeding Were a history of diabetes, hypertension,dyslipidemia, cardio-vascular, kidney, and liver diseases,and cancer Having body mass index (BMI) equal or more than 30 Take any medicine, especially in the last six months, such as: medicine to control (hot flashes, blood lipids, blood pressure, diabetes), multivitamins, chemotherapy, immunosuppressant and hormone replacement therapy drugs or alcohol, smoking
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Low Density Lipoprotein-cholestrol (LDL-Cl). Timepoint: Before and immediately after the intervention in each phase which is 28 days and the time period between them is 8 days. Method of measurement: An intravenous sample of a 12 hours overnight fasting blood test and record in the follow up form.;Hot flashes symptom. Timepoint: Number and sevierity of hot flashes before and immediately after the intervention in each phase and daily record of hot flashes during each phase by subjects. Method of measurement: Hot flashes daily record by subjects and determine severity score of hot flashes by investigator according to Modified Kupperman Index and the classification of the number of hot flashes and weight factor.;Triglyceride (TG). Timepoint: Before and immediately after the intervention in each phase which is 28 days and the time period between them is 8 days. Method of measurement: An intravenous sample of a 12 hours overnight fasting blood test and record in the follow up form.;Total cholestrol (TC). Timepoint: Before and immediately after the intervention in each phase which is 28 days and the time period between them is 8 days. Method of measurement: An intravenous sample of a 12 hours overnight fasting blood test and record in the follow up form.;High Density Lipoprotein-cholestrol (HDL-C). Timepoint: Before and immediately after the intervention in each phase which is 28 days and the time period between them is 8 days. Method of measurement: An intravenous sample of a 12 hours overnight fasting blood test and record in the follow up form.;Nitric Oxide. Timepoint: Before and immediately after the intervention in each phase which is 28 days and the time period between them is 8 days. Method of measurement: An intravenous sample of a 12 hours overnight fasting blood test and record in the follow up form. | — |
Secondary
| Measure | Time frame |
|---|---|
| . Timepoint: ---------------------. Method of measurement: ---------------------. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNahid Elliyoun
Shahid Beheshti School of Nursing and Midwifery
Outcome results
None listed